Brian Matthew Wolpin, M.D.
Co-Author
This page shows the publications co-authored by Brian Wolpin and Jonathan Nowak.
Connection Strength
2.788
-
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Oct; 11(10):2488-2505.
Score: 0.240
-
Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clin Cancer Res. 2021 02 15; 27(4):1069-1081.
Score: 0.233
-
Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol. 2020 10 01; 6(10):e202948.
Score: 0.230
-
Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1586-1595.
Score: 0.225
-
Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1868-1875.
Score: 0.213
-
Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer. 2019 04; 120(8):848-854.
Score: 0.207
-
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
Score: 0.197
-
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
Score: 0.196
-
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
Score: 0.193
-
Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018 08; 16(8):1300-1306.e3.
Score: 0.192
-
Statin use and pancreatic cancer risk in two prospective cohort studies. J Gastroenterol. 2018 Aug; 53(8):959-966.
Score: 0.191
-
Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017 Dec 05; 117(12):1874-1882.
Score: 0.187
-
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 Jul 20.
Score: 0.061
-
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15; 27(16):4574-4586.
Score: 0.060
-
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021 Aug; 11(8):2014-2031.
Score: 0.059
-
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell. 2020 05 14; 181(4):832-847.e18.
Score: 0.056
-
Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget. 2017 Oct 20; 8(50):87379-87389.
Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.